Prognostic factors and analysis of mortality due to brain haemorrhages associated with vitamin K antagonist oral anticoagulants. Results from the TAC registry
Neurologia (Engl Ed). 2018 Sep;33(7):419-426.
doi: 10.1016/j.nrl.2016.07.005.
Epub 2016 Sep 16.
[Article in
English,
Spanish]
Authors
G Zapata-Wainberg
1
, S Quintas
2
, A Ximénez-Carrillo Rico
2
, L Benavente Fernández
3
, J Masjuan Vallejo
4
, J Gállego Culleré
5
, M Del M Freijó Guerrero
6
, J Egido
7
, J C Gómez Sánchez
8
, A Martínez Domeño
9
, F Purroy
10
, B Vives Pastor
11
, M Rodríguez Yáñez
12
, J Vivancos
2
; en representación del grupo de investigadores del estudio TAC Registry
Affiliations
- 1 Servicio de Neurología, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria La Princesa, Madrid, España. Electronic address: [email protected].
- 2 Servicio de Neurología, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria La Princesa, Madrid, España.
- 3 Servicio de Neurología, Hospital Universitario Central de Asturias, Oviedo, España.
- 4 Servicio de Neurología, Hospital Universitario Ramón y Cajal, IRYCIS, Universidad de Alcalá.
- 5 Servicio de Neurología, Complejo Hospitalario de Navarra, Pamplona, Navarra, España.
- 6 Servicio de Neurología, Hospital Universitario Basurto Bilbao, Vizcaya, España.
- 7 Servicio de Neurología, Hospital Universitario Clínico San Carlos, Madrid, España.
- 8 Servicio de Neurología, Hospital Universitario de Salamanca, Salamanca, España.
- 9 Servicio de Neurología, Hospital de la Santa Creu i Sant Pau, Barcelona, España.
- 10 Servicio de Neurología, Hospital Universitari Arnau de Vilanova, Lleida, España.
- 11 Servicio de Neurología, Hospital Universitari Son Espases, Mallorca, Islas Baleares, España.
- 12 Servicio de Neurología, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, España.
Abstract
Introduction:
Intracranial haemorrhages (ICH) represent a severe and frequently lethal complication in patients treated with vitamin K antagonists (VKA). The purpose of our study is to describe the factors and clinical features associated with mortality in these patients.
Methods:
We conducted an observational, retrospective, multi-centre study based on prospective stroke registries in Spain. We included all patients admitted to neurology departments during a one-year period who met the following inclusion criteria: being 18 or older, having a diagnosis of ICH, and receiving VKA. Clinical and radiological parameters and 3-month outcomes were analysed.
Results:
A total of 235 patients from 21 hospitals were included. Mortality rate at 90 days was 42.6%. Bivariate analysis showed a significant association between death and the following factors: median NIHSS score at admission (5 [IQR = 9] vs 17 [IQR = 14] points, P<.01) and presence of an extensive hemispheric haemorrhage (4.9% vs 35%, P < .01; χ2). Extensive hemispheric haemorrhages, in addition to being the most lethal type, were associated with a shorter time to death (mean of 16.5 days; 95% CI: 7.1-26). A logistic regression model showed that only baseline NIHSS scores independently predicted death (odds ratio=1.13 [95% CI: 1.08-1.17] for each point in the scale).
Conclusion:
ICH in patients treated with VKA is associated with high mortality rates; mortality in these patients is mainly and independently associated with the clinical situation at stroke onset.
Keywords:
Acenocoumarol; Acenocumarol; Anticoagulantes orales; Hemorragia cerebral; Intracranial haemorrhage; Mortalidad; Mortality; Oral anticoagulants; Warfarin; Warfarina.
Copyright © 2016 Sociedad Española de Neurología. Publicado por Elsevier España, S.L.U. All rights reserved.
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Anticoagulants / adverse effects*
-
Anticoagulants / therapeutic use
-
Cause of Death
-
Cerebral Hemorrhage / chemically induced*
-
Cerebral Hemorrhage / mortality*
-
Female
-
Humans
-
Middle Aged
-
Prognosis
-
Registries
-
Retrospective Studies
-
Spain / epidemiology
-
Stroke / complications
-
Vitamin K / antagonists & inhibitors*
-
Young Adult